What Happened to Clarus Therapeutics Holdings?
Return
0.0%
Current Price
$0
Peak Price
â
Trust Size
$49M
Summary
Clarus Therapeutics was a pharmaceutical company that developed JATENZO, the first FDA-approved oral testosterone replacement therapy for men with hypogonadism. The company went public via SPAC merger with Blue Water Acquisition Corp in 2021. Clarus filed for Chapter 11 bankruptcy in September 2022.
What Happened
Blue Water Acquisition Corp merged with Clarus Therapeutics in September 2021. Despite having an FDA-approved product (JATENZO), the company struggled with commercial launch, facing competition and slow physician adoption. Just one year after going public, Clarus filed for Chapter 11 in September 2022, making it one of the quickest SPAC-to-bankruptcy cases.
Timeline
2020-11-30
S-1 Registration Filed
2023-03-06
Last SEC Filing